3.00Open3.00Pre Close0 Volume124 Open Interest2.50Strike Price0.00Turnover0.00%IV-12.28%PremiumJan 17, 2025Expiry Date3.77Intrinsic Value100Multiplier-3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.67Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Torrid Stock Discussion
Dow Jones· 3 mins ago
Torrid Reports Third Quarter Fiscal 2024 Results
5 minutes ago, 1:05 PM PST
Via BusinessWire
• Delivered Net Sales of $263.8 million
• Generated gross margin expansion of 285 basis points to 36.1%
• Net Loss of $1.2 million compared to Net Loss of $2.7 million last year
• Updated 2024 Net Sales and Adjusted EBITDA(1) Outlook
📊⚡️📊
$Yield10 Bioscience (YTEN.US)$ $Lytus Technologies Holdings (LYT.US)$ $Avalo Therapeutics (AVTX.US)$ $Gamida Cell (GMDA.US)$ $Torrid (CURV.US)$ $Qilian International (QLI.US)$
📊⚡️📊
📊⚡️📊
CURV soared 26% to trade at $6.15 shortly before 4:45 p.m. ET after the company reported a $0.04 loss per share – narrower than the $0.07 analysts had reportedly expected.
The company also recorded $293.5 million of quarterly revenues vs. the $276....
No comment yet